- Generic name
- Sacubitril + Valsartan
- Strength
- 97 mg + 103 mg
- Dosage form
- Tablet
- Manufactured by
- Renata PLC.
ENTROVAS-97/103 Tablet
About ENTROVAS-97/103 Tablet
ENTROVAS-97/103 is a tablet combining sacubitril and valsartan, used in heart failure. It contains a neprilysin inhibitor and an angiotensin receptor blocker, and is available as a 97 mg + 103 mg tablet.
There are 25 brands of Sacubitril + Valsartan listed in Bangladesh. The lowest listed price is Arnis 24 mg+26 mg Tablet at ৳ 35.00 per unit.
What is ENTROVAS-97/103 Tablet?
ENTROVAS-97/103 is a tablet medicine that combines two active substances: sacubitril and valsartan. Sacubitril belongs to a group called neprilysin inhibitors, and valsartan is an angiotensin receptor blocker. Together they are used in the treatment of heart failure. The tablet is made by Renata PLC. It is available in a strength of 97 mg + 103 mg. Heart failure is a long-term condition, and treatment should be managed by a doctor who can decide whether this medicine is suitable.
Uses of ENTROVAS-97/103
ENTROVAS-97/103 is used to reduce the risk of cardiovascular death and hospitalization for heart failure in adults with chronic heart failure and reduced ejection fraction. It is also used for symptomatic heart failure with left ventricular systolic dysfunction in children aged one year and older. Your doctor will assess your condition and decide if this medicine is appropriate for you.
How to use ENTROVAS-97/103
ENTROVAS-97/103 is taken by mouth as a tablet. The doctor decides the dose and how often you take it, including any change in dose over time. Do not adjust the dose yourself. Swallow the tablet as directed by your doctor. If you miss a dose, ask your doctor or pharmacist what to do. Keep all appointments so your doctor can check your progress and adjust treatment if needed.
Side effects of ENTROVAS-97/103
Like all medicines, ENTROVAS-97/103 can cause side effects. The most common ones include angioedema, low blood pressure, impaired kidney function, high potassium levels, cough, and dizziness. Some side effects can be serious. Tell your doctor promptly if you notice swelling, difficulty breathing, or a big drop in blood pressure. Your doctor may monitor your kidney function and potassium levels during treatment.
Safety and precautions
ENTROVAS-97/103 must not be used by anyone with a known allergy to any ingredient, or with a history of angioedema linked to an ACE inhibitor or ARB. It should not be taken with ACE inhibitors, or with aliskiren in people with diabetes. It is not recommended in severe liver impairment. Tell your doctor if you are pregnant, planning pregnancy, or breastfeeding. Also inform your doctor about kidney problems, high potassium, or other medicines you take, so they can decide if it is safe for you.
Frequently asked questions
What is ENTROVAS-97/103 used for and what kind of medicine is it?
ENTROVAS-97/103 is a combination tablet of sacubitril and valsartan. It is used to treat heart failure in adults and in children aged one year and older. Sacubitril is a neprilysin inhibitor and valsartan is an angiotensin receptor blocker. Your doctor will decide if it is right for you.
Who should avoid ENTROVAS-97/103 or ask the doctor first?
Do not take it if you have had angioedema with an ACE inhibitor or ARB, or if you are allergic to any ingredient. Avoid it with ACE inhibitors or with aliskiren if you have diabetes. Ask your doctor first if you are pregnant, breastfeeding, have kidney or liver problems, or take other medicines.
How should ENTROVAS-97/103 be taken?
Take the tablet by mouth as instructed by your doctor. The doctor decides the dose and how often you take it, and may change the dose over time. Do not change the dose yourself. If you miss a dose, ask your doctor or pharmacist for advice. Keep your appointments for monitoring.
What should I tell my doctor before starting ENTROVAS-97/103?
Tell your doctor about any allergies, especially swelling problems, and all other medicines you take, including ACE inhibitors, potassium-sparing diuretics, NSAIDs, or lithium. Mention if you have kidney or liver problems, high potassium, or if you are pregnant or breastfeeding. Your doctor will decide if this medicine is suitable.
Indications
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older. ... Read more
- To reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class ll-IV) and reduced ejection fraction.
- For the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.
- This is usually administered in conjunction with other heart failure therapies, in place of an angiotensin-converting enzyme inhibitor (ACEi) or other ARB.
Pharmacology
Dosage & Administration
Reduce the starting dose to 24/26 mg twice daily for:
- Patients not currently taking an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin II receptor blocker (ARB) or previously taking a low dose of these agents.
- Patients with severe renal impairment.
- Patients with moderate hepatic impairment.
Recommended Dose Titration-
Pediatric Patients Less than 40 kg:
- Starting: 1.6 mg/kg
- Second: 2.3 mg/kg
- Final: 3.1 mg/kg
- Starting: 24/26 mg
- Second: 49/51 mg
- Final: 49/51 mg
- Starting: 49/51 mg
- Second: 72/78 mg
- Final: 97/103 mg
Interaction
Potassium-sparing Diuretics: Serum potassium level may be increased.
NSAIDs: Risk of renal impairment may be increased.
Lithium: Increased risk of lithium toxicity.
Contraindications
- In patients with hypersensitivity to any component
- In patients with a history of angioedema related to previous ACE inhibitor or ARB therapy
- With concomitant use of ACE inhibitors. Do not administer within 36 hours of switching from or to an ACE inhibitor
- With concomitant use of aliskiren in patients with diabetes
Side Effects
Pregnancy & Lactation
Geriatric Use: No relevant pharmacokinetic differences have been observed in elderly (>65 years) or very elderly (>75 years) patients compared to the overall population.
Hepatic Impairment: No dose adjustment is required when administering this tablet to patients with mild hepatic impairment (Child-Pugh A classification). This tablet is not recommended in patients with severe hepatic impairment, as no studies have been conducted in these patients.
Renal Impairment: No dose adjustment is required in patients with mild (eGFR 60 to 90 ml/min/1.73 m2) to moderate (eGFR 30 to 60 ml/min/1.73 m2) renal impairment. The recommended starting dose in patients with severe renal impairment (eGFR <30 ml/min/1.73 m2) is 24/26 mg twice daily.
Precautions & Warnings
This tablet lowers blood pressure and may cause symptomatic hypotension. Closely monitor serum creatinine, and down-titrate or interrupt this tablet in patients who develop a clinically significant decrease in renal function. In patients with renal artery stenosis, monitor renal function.
Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism, or a high potassium diet. Dosage reduction or interruption of this tablet may be required.
Overdose Effects
Storage Conditions
Alternative brands of Sacubitril + Valsartan
Other brands with the same generic name, cheapest first.
Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.